| Recruiting | Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias NCT06364423 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Active Not Recruiting | Trial of Anti-CD19 and Anti-CD20 Bicistronic Chimeric Antigen Receptor T Cells for Treating B-Cell Malignancie NCT05797233 | National Cancer Institute (NCI) | Phase 1 |
| Recruiting | A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+ NCT05645107 | Grifols Therapeutics LLC | Phase 3 |
| Unknown | "Don't Eat me" Signal in Hematological Malignancies: CD24 as New Target to Improve Anti-cancer Immunity. NCT05888701 | University of Milano Bicocca | — |
| Terminated | CAR20.19.22 T-cells in Relapsed, Refractory B-cell Malignancies NCT05094206 | Medical College of Wisconsin | Phase 1 |
| Completed | Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLL NCT04030195 | Precision BioSciences, Inc. | Phase 1 / Phase 2 |
| Terminated | T Cells Expressing Fully-human Anti-CD19 and Anti-CD20 Chimeric Antigen Receptors for Treating B-cell Malignan NCT04160195 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Ibrutinib, Obinutuzumab and Venetoclax for Patients With Chronic Lymphocytic Leukemia NCT03755947 | Grupo Cooperativo de Hemopatías Malignas | Phase 2 |
| Terminated | Idelalisib Post Allogeneic Hematopoietic Stem Cell Transplant (HSCT) in B Cell Derived Malignancies NCT03151057 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 1 |
| Completed | A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies NCT03088878 | Oncternal Therapeutics, Inc | Phase 1 / Phase 2 |
| Unknown | A Phase I Study of YY-20394 in Patients With B Cell Hematologic Malignancies NCT03757000 | Shanghai YingLi Pharmaceutical Co. Ltd. | Phase 1 |
| Completed | Tolerance and Resistance to Ibrutinib in Patients With Chronic Lymphocytic Leukemia (CLL NCT03502876 | French Innovative Leukemia Organisation | — |
| Completed | Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Sma NCT03204188 | National Heart, Lung, and Blood Institute (NHLBI) | Phase 2 |
| Completed | Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 an NCT03097770 | Chinese PLA General Hospital | Phase 1 / Phase 2 |
| Unknown | Anti-CD19 CAR T Infusion Combined With Allogeneic Stem Cell Transplantation for B-cell Leukemia/Lymphoma NCT03110640 | First Affiliated Hospital of Wenzhou Medical University | Phase 1 |
| Unknown | Competitive Transfer of αCD19-TCRz-CD28 and αCD19-TCRz-CD137 CAR-T Cells for B-cell Leukemia/Lymphoma NCT02685670 | The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine | Phase 1 / Phase 2 |
| Terminated | A Study Evaluating the Safety of Tocilizumab in Addition to Standard of Care Premedication Given Before Obinut NCT02336048 | Hoffmann-La Roche | Phase 1 |
| Completed | Interaction Study of Ibrutinib and Cytochrome P450 (CYP) 3A Inhibitors in Participants With B-cell Malignancy NCT02381080 | Janssen Research & Development, LLC | Phase 1 |
| Terminated | A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors NCT02440685 | Asana BioSciences | Phase 1 / Phase 2 |
| Unknown | Pilot Study of Autologous T Lymphocytes With ADCC in Patients With CD20-Positive B-Cell Malignancies NCT02315118 | National University Hospital, Singapore | Phase 1 / Phase 2 |
| Terminated | CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non NCT02168907 | Wake Forest University Health Sciences | Phase 1 |
| Withdrawn | B-Cell Hematologic Malignancy Vaccination Registry NCT02298816 | Wake Forest University Health Sciences | — |
| Completed | Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphom NCT02213913 | University of Chicago | Phase 1 / Phase 2 |
| Completed | Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hemato NCT01789255 | National Cancer Institute (NCI) | Phase 2 |
| Unknown | Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by CART19 NCT01864889 | Chinese PLA General Hospital | N/A |
| Terminated | Treatment of B-CLL With Autologous IL2 and CD40 Ligand-Expressing Tumor Cells + Lenalidomide NCT01604031 | Baylor College of Medicine | Phase 1 |
| Unknown | Genetically Engineered Lymphocyte Therapy in Treating Patients With Lymphoma That is Resistant or Refractory t NCT01735604 | Chinese PLA General Hospital | Phase 1 / Phase 2 |
| Completed | Rituximab in Pretreated Elderly or Unfit B-CLL Patients NCT01576588 | Prof. Dr. Med. Laimonas Griskevicius | Phase 2 |
| Completed | Bortezomib and Filgrastim to Promote Stem Cell Mobilization in Patients With Non-Hodgkin Lymphoma or Multiple NCT02037256 | Barbara Ann Karmanos Cancer Institute | N/A |
| Suspended | Phase II Clinical Trial of Alemtuzumab to Treat B-cell Chronic Lymphocytic Leukemia NCT01982175 | Shanghai Zhangjiang Biotechnology Limited Company | Phase 2 |
| Completed | Safety and Tolerability Study of PCI-32765 Combined With Fludarabine/Cyclophosphamide/Rituximab (FCR) and Bend NCT01292135 | Pharmacyclics LLC. | Phase 1 |
| Completed | Imprime PGG, Alemtuzumab, and Rituximab in Treating Patients With High Risk Chronic Lymphocytic Leukemia NCT01269385 | Mayo Clinic | Phase 1 / Phase 2 |
| Completed | Efficacy and Safety Study of PCI-32765 Combine With Ofatumumab in CLL NCT01217749 | Pharmacyclics LLC. | Phase 1 / Phase 2 |
| Completed | Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma NCT01258998 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Study of Carfilzomib in Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) or Prolymphocytic NCT01212380 | Ohio State University Comprehensive Cancer Center | Phase 1 |
| Completed | Study of Bafetinib as Treatment for Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL) NCT01144260 | CytRx | Phase 2 |
| Completed | Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia NCT01109069 | Pharmacyclics LLC. | Phase 2 |
| Completed | Safety of PCI-32765 in Chronic Lymphocytic Leukemia NCT01105247 | Pharmacyclics LLC. | Phase 1 / Phase 2 |
| Terminated | Alvespimycin Hydrochloride in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic NCT01126502 | National Cancer Institute (NCI) | Phase 1 |
| Completed | ABT-348 as Monotherapy and in Combination With Azacitidine to Treat Advanced Hematologic Malignancies NCT01110473 | AbbVie (prior sponsor, Abbott) | Phase 1 |
| Completed | CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to Chemotherapy NCT01029366 | University of Pennsylvania | Phase 1 |
| Withdrawn | Study Assessing the Safety and Efficacy of ABT-263 in Subjects With B-cell Chronic Lymphocytic Leukemia (CLL) NCT00918450 | Abbott | Phase 2 |
| Terminated | Lenalidomide as Chemoprevention in Treating Patients With High-Risk, Early-Stage B-Cell Chronic Lymphocytic Le NCT01649791 | Roswell Park Cancer Institute | N/A |
| Completed | Study Of The Effectiveness & Safety Of Lenalidomide Versus Chlorambucil As First Line Therapy For Elderly Pati NCT00910910 | Celgene | Phase 3 |
| Completed | Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refracto NCT00867529 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | A Study to Evaluate the Efficacy and Safety of Lenalidomide as Maintenance Therapy for Patients With B-Cell Ch NCT00774345 | Celgene | Phase 3 |
| Withdrawn | Fludarabine Phosphate, Rituximab, and Bevacizumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemi NCT00845104 | Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium | Phase 2 |
| Completed | Study of MLN8237 in Participants With Advanced Hematological Malignancies NCT00697346 | Millennium Pharmaceuticals, Inc. | Phase 1 |
| Terminated | Trial of Forodesine in Patients With Relapsed B-cell Chronic Lymphocytic Leukemia NCT00646165 | Mundipharma Research Limited | Phase 1 |
| Terminated | Hydroxychloroquine in Untreated B-CLL Patients NCT00771056 | Northwell Health | Phase 2 |
| Terminated | Safety and Dose Ranging Study of Samalizumab to Treat Relapsing or Refractory CLL or MM NCT00648739 | Alexion Pharmaceuticals, Inc. | Phase 1 / Phase 2 |
| Terminated | Obatoclax, Fludarabine, and Rituximab in Treating Patients With Previously Treated Chronic Lymphocytic Leukemi NCT00612612 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Genetically Engineered Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Relapsed or Re NCT00621452 | Fred Hutchinson Cancer Center | Phase 1 |
| Completed | Sunitinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic L NCT00398112 | National Cancer Institute (NCI) | Phase 2 |
| Withdrawn | Study Evaluating Effects of CX-3543 in Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemi NCT00485966 | Cylene Pharmaceuticals | Phase 2 |
| Completed | A Phase I/II Study to Assess the Safety and Tolerability of APO866 for the Treatment of Refractory B-CLL NCT00435084 | Valerio Therapeutics | Phase 1 / Phase 2 |
| Terminated | Alvocidib in Treating Patients With B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma NCT00377104 | National Cancer Institute (NCI) | Phase 1 |
| Unknown | Low Dose Alemtuzumab for Consolidation and Maintenance of Patients With B-Cell Chronic Lymphocytic Leukemia NCT00336206 | Tawam Hospital | N/A |
| Completed | AZD2171 in Treating Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia NCT00321724 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | A Study to Evaluate the Treatment of Previously Untreated B-Cell Chronic Lymphocytic Leukemia (B-CLL) NCT00302861 | Genitope Corporation | Phase 1 / Phase 2 |
| Terminated | Phase 1, Dose-Escalation Study of Oral CNF2024(BIIB021) in CLL NCT00344786 | Biogen | Phase 1 |
| Completed | Bevacizumab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia NCT00290810 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma NCT00288067 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Terminated | 17-N-Allylamino-17-Demethoxygeldanamycin With or Without Rituximab in Treating Patients With Relapsed B-Cell C NCT00098488 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Flavopiridol in Treating Patients With Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia NCT00098371 | National Cancer Institute (NCI) | Phase 2 |
| Unknown | Interventional Study on Pentostatin, Cyclophosphamide and Rituximab in Indolent B-Cell Non-Hodgkin-Lymphoma (B NCT00927797 | Heidelberg University | Phase 2 |
| Completed | Fludarabine, Cyclophosphamide, and Alemtuzumab in Patients With B-cell Chronic Lymphatic Leukemia (B-CLL) NCT00147901 | German CLL Study Group | Phase 2 |
| Terminated | Oxaliplatin, Ifosfamide and Etoposide in Treating Young Patients With Recurrent or Refractory Solid Tumors or NCT00101205 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Fludarabine, Rituximab, and Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia NCT00098670 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Fludarabine (Fludara®) Plus Alemtuzumab (CAMPATH®, MabCampath®) vs Fludarabine Alone in B-Cell Chronic Lymphoc NCT00086580 | Genzyme, a Sanofi Company | Phase 3 |
| Completed | Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating NCT00119392 | Fred Hutchinson Cancer Center | Phase 2 |
| Terminated | MDX-010 in Treating Patients With Recurrent or Refractory Lymphoma NCT00089076 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | CCI-779 in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic NCT00290472 | National Cancer Institute (NCI) | Phase 2 |
| Completed | A Pilot Trial With Subcutaneous Alemtuzumab and Oral Fludarabinephosphate for the Determination of Safety, Eff NCT00565981 | Arbeitsgemeinschaft medikamentoese Tumortherapie | Phase 2 |
| Unknown | Study of Subcutaneous Campath-1H in Patients With B-Cell CLL and Residual Disease After Chemotherapy NCT00800943 | Chronic Lymphocytic Leukemia Research Consortium | Phase 2 |
| Completed | Fludarabine, Cyclophosphamide, and Rituximab Versus Pentostatin, Cyclophosphamide, and Rituximab in Previously NCT00254163 | US Oncology Research | Phase 3 |
| Completed | Flavopiridol in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia or Lymphocytic Lymphoma NCT00058240 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Alvocidib, Fludarabine Phosphate, and Rituximab in Treating Patients With Lymphoproliferative Disorders or Man NCT00058227 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Efficacy/Safety of Frontline Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B- NCT00046683 | Genzyme, a Sanofi Company | Phase 3 |
| Completed | Thalidomide in Treating Patients With Relapsed Chronic Lymphocytic Leukemia NCT00006226 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Fludarabine Phosphate, Low-Dose Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients Wi NCT00005799 | Fred Hutchinson Cancer Center | N/A |
| Completed | Flavopiridol in Treating Patients With Chronic Lymphocytic Leukemia NCT00003620 | National Cancer Institute (NCI) | Phase 2 |
| Approved For Marketing | Early Access Program (EAP) for Ibrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leuke NCT02437019 | Janssen-Cilag Farmaceutica Ltda. | — |